The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.
- 1 August 2008
- journal article
- review article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 86 (8) , 473-484
Abstract
The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ETAR and ETBR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi’s sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.Keywords
This publication has 76 references indexed in Scilit:
- Mitogenic signaling pathways induced by G protein‐coupled receptorsJournal of Cellular Physiology, 2007
- On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancerBreast Cancer Research and Treatment, 2007
- A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaInvestigational New Drugs, 2006
- Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate CancerNeoplasia, 2006
- Bosentan® inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasisClinical & Experimental Metastasis, 2006
- Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinomaEuropean Journal of Cancer, 2005
- Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor ratsBreast Cancer Research and Treatment, 2005
- Functional role of matrix metalloproteinases in ovarian tumor cell plasticityAmerican Journal of Obstetrics and Gynecology, 2004
- Regulation and Intracellular Trafficking Pathways of the Endothelin ReceptorsJournal of Biological Chemistry, 2000
- The Hallmarks of CancerCell, 2000